Pacific Biosciences of California (PACB) said Thursday it has appointed Chris Smith, chief executive of NeoGenomics (NEO), to the board of directors, effective immediately.
Smith has extensive experience in the life sciences and healthcare industries and led growth and innovation at NeoGenomics in precision medicine, Pacific Biosciences said.
The company said David Meline is resigning from its board, effective immediately, after contributing to the company's strategy since 2023.
Shares of Pacific Biosciences were up 1.9% and NeoGenomics rose 2.8% in recent trading.
Price: 1.59, Change: +0.03, Percent Change: +1.92
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。